Ashton Agar looks set to play his first cricket Test in four years against Bangladesh on Sunday after coach Darren Lehmann suggested Australia would go with two spinners for the series opener in Mirpur.The 23-year-old left-arm finger spinner made his Test debut as a teenager in the 2013 Ashes series, starring more with bat than ball in two matches against England that remain his only experience of the longest form of the game.With Steven O’Keefe having been dropped despite a brilliant tour of India earlier this year, however, Agar is in the driving seat to get the nod ahead of uncapped leg-spinner Mitchell Swepson in a twin spin attack with Nathan Lyon.The tourists were robbed of their only practice match by the Dhaka rain on Monday, which Lehmann said made it even less likely he would radically overhaul his team from that which finished the tour of India in March.”We obviously haven’t played too much, so we’re fairly settled in where we want to go,” he told reporters in the Bangladesh capital.”That decision will be made later, once we start to have a look at the test wicket and the conditions. Most likely, I think we’ll play two spinners.”Agar toured India with Australia earlier this year but never got a chance to play as his fellow left-armer O’Keefe took 19 wickets at an average of 23.26, including 12 in the first test at Pune.O’Keefe, 32, was fined A$20,000 ($15,838) for “highly inappropriate behaviour” towards a female cricketer while drunk at an award ceremony in April, however, and was dumped for the Bangladesh tour in favour of the younger man.advertisement”Steven was excellent over there but we’ve decided to go with Ashton,” Lehmann said.”He’s got the all-round game and hopefully he’ll take it to the next level so if we wanted to play three quicks he could bat up the order, for example. He gives us a lot of flexibility in that way.”Young Swepson is a good prospect as a leg-spinner…it’s really tight between all the spinners but Ashton himself has batted really well, he’s a gun fielder and he’s got his length right with the ball.”The first Test starts on Sunday with the second in Chittagong scheduled from September 4-8.
David Ortiz received a qualifying offer from the Boston Red Sox on Friday for $13. 3 million before Friday’s the 5 p.m. ET deadline set by MLB.The team and Ortiz are negotiating a two-year deal that is “very close” to being completed according to sources, but the exact amount of the contract is still being negotiated.“David is someone who we feel strongly about bringing back, and we’re trying to figure out a way to do that and we hope that happens,” Red Sox general manager Ben Cherington said earlier this week.Ortiz will become a free agent by midnight Friday if they can’t come to an agreement, which will allow him to talk to other teams. The qualifying offer is less than the $14.48 million he earned in 2012, but has until Nov. 9 to accept the offer. The Red Sox strategically gave the designated hitter the qualifying to ensure if he signs with another team they can receive draft picks as compensation.One of the teams that has expressed interest in Ortiz is the Texas Rangers. They envision Ortiz as a left-handed hitter who could replace Josh Hamilton, who is a free agent and received a qualifying offer from the Rangers. The Rangers feel Ortiz could the clubhouse more of an edge.Ortiz will turn 37 on Nov. 18, missed the last 71 of 72 games due to a right Achilles strain he suffered on July 16. The eight-time All-Star finished the season with a 23 home runs, 60 RBIs, and a .318 batting average in 90 games.In 2003, Ortiz joined the Red Sox and was a central figure in helping the club win the 2004 and 2007 World Series. One-year deals are noting new to Ortiz, who has been in one each of the past two seasons. The Red Sox exercised his $12.5 million option for 2011, and Ortiz accepted arbitration in 2012, settling on a $14.575 million salary.Ortiz has made his desire to stay in Boston public and is fond of team’s new manager, John Farrell.“Something will get done,” Ortiz told the Boston Globe about signing a new deal with the team. “I feel good about it.”
More information: Rong-Hui Deng. Mei-Zhen Zou, Diwei Zheng, Si-Yuan Peng, Wenlong Liu, Xue-Feng Bai, Han-Shi Chen, Yunxia Sun, Pang-Hu Zhou, and Xian-Zheng Zhang. “Nanoparticles from Cuttlefish Ink Inhibit Tumor Growth by Synergizing Immunotherapy and Photothermal Therapy.” ACS Nano. DOI: 10.1021/acsnano.9b02993 Researchers have found that cuttlefish ink—a black suspension sprayed by cuttlefish to deter predators—contains nanoparticles that strongly inhibit the growth of cancerous tumors in mice. The nanoparticles consist mostly of melanin by weight, along with amino acids, monosaccharides (simple sugars), metals, and other compounds. The researchers showed that the nanoparticles modify the immune function in tumors, and when combined with irradiation, can almost completely inhibit tumor growth. Due to these costs, some researchers have turned to nature for alternatives. Previous research has shown that certain natural compounds, including those found in brown algae and some bacteria, contain polysaccharides that have the ability to reprogram macrophages from the M2 type to the M1 type. In the new paper, the researchers found that cuttlefish ink nanoparticles, which are spherical and approximately 100 nm in diameter, also have this ability. After confirming the biocompatibility of these nanoparticles, the researchers performed several experiments both in vitro with tumor cells and in vivo with tumor-afflicted mice. In the in vitro experiments, the researchers found that irradiating the nanoparticles with near-infrared irradiation killed approximately 90% of tumor cells, although the nanoparticles displayed almost no cytotoxicity without irradiation. The researchers explained that the high melanin content of the nanoparticles plays a key role in the irradiation process, as melanin has an intrinsically good photothermal conversion ability.In mice, nanoparticle treatment proved to be effective both alone and in combination with irradiation, although irradiation further improved the outcome. Bioluminescent imaging revealed that treated mice exhibited significantly lower tumor bioluminescence compared to controls, indicating greatly reduced metastases on internal organs. Mice treated with both nanoparticles and irradiation exhibited a nearly complete inhibition of tumor growth.By performing a gene analysis, the researchers identified 194 differentially expressed genes involved in immune functions that were associated with the regulation of the inflammatory response and cell killing, and which were either up- or down-regulated by the treatment. The analysis indicated that a certain signaling pathway is responsible for the conversion of M2 macrophages to M1 macrophages. This mechanism not only leads to phagocytosis of tumor cells, but also stimulates the immune system to produce various antitumor factors, all of which play a role in inhibiting tumor growth.In the future, the researchers plan to explore other natural materials that have anti-cancer properties.”Our research team is currently studying the biomedical potential of natural materials such as hair, cuttlefish ink, bacteria, fungi, and even the cells of the human body as a therapeutic drug carrier,” Zhang said. “By drawing inspiration from nature and taking advantage of its own characteristics, we expect to find some valuable research that will provide new and effective solutions for the treatment of clinical diseases.” Journal information: ACS Nano Explore further Citation: Cuttlefish ink found promising for cancer treatment (2019, July 22) retrieved 18 August 2019 from https://phys.org/news/2019-07-cuttlefish-ink-cancer-treatment.html © 2019 Science X Network This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only. Elegant antibody nanoparticles override immunological tolerance of tumors (Left) A cuttlefish. Credit: North Atlantic Stepping Stones Science Party, IFE, URI-IAO; NOAA/OAR/OER. (Right) Comparison of tumor size after 16 days of different treatments, including cuttlefish ink nanoparticles (CINPs) and CINPs with irradiation. Credit: Deng et al. ©2019 American Chemical Society The researchers, led by Pang-Hu Zhou at the Renmin Hospital of Wuhan University and Xian-Zheng Zhang at the Chemistry Department at Wuhan University, have published a paper on the ability of nanoparticles from cuttlefish ink to inhibit tumor growth in a recent issue of ACS Nano.”We found natural nanoparticles from cuttlefish ink with good biocompatibility that can effectively achieve tumor immunotherapy and photothermal therapy simultaneously,” Zhang told Phys.org. “This finding might inspire more exploration of natural materials for medical applications.”Tumor immunotherapy involves fighting cancer by stimulating the body’s own immune system. One strategy is to target leukocytes, or white blood cells. Macrophages are the predominant leukocyte found in some tumors, and they can take one of two forms: M1 or M2. The M1 phenotype engulfs and destroys tumor cells through the process of phagocytosis and with the activation of T cells (other white blood cells). In the M2 phenotype, on the other hand, this immune function is suppressed, allowing tumor growth to continue unchecked. In tumor environments, the M2 phenotype almost always outnumbers the M1 phenotype.Recently, researchers have been working on the development of small molecules and antibodies that can convert protumor M2 macrophages to antitumor M1 macrophages. At the same time, they are designing nanoparticles such as photothermal agents that, when exposed to irradiation, locally destroy cancer cells by thermal ablation. These agents can be integrated into synthesized nanoparticles, and then potentially administered to patients. One of the drawbacks, however, is that these synthetic nanoparticles are expensive and require complicated preparation methods.